Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Rimonabant

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,430Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 168273-06-1, Acomplia, Zimulti, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide, Sr141716, Rimoslim
    Molecular Formula
    C22H21Cl3N4O
    Molecular Weight
    463.8  g/mol
    InChI Key
    JZCPYUJPEARBJL-UHFFFAOYSA-N
    FDA UNII
    RML78EN3XE
    A pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and maturation of ADIPOCYTES, improves lipid and glucose metabolism, and regulates food intake and energy balance. It is used in the management of OBESITY.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
    2.1.2 InChI
    InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
    2.1.3 InChI Key
    JZCPYUJPEARBJL-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    RML78EN3XE
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Acomplia

    2. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide Hydrochloride

    3. Rimonabant Hydrochloride

    4. Sr 141716

    5. Sr 141716a

    6. Sr-141716a

    7. Sr141716

    8. Sr141716a

    9. Zimulti

    2.3.2 Depositor-Supplied Synonyms

    1. 168273-06-1

    2. Acomplia

    3. Zimulti

    4. 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide

    5. Sr141716

    6. Rimoslim

    7. Sr 141716

    8. Sr141716a

    9. Sr-141716a

    10. A 281

    11. Rimonabant Free Base

    12. 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidin-1-ylpyrazole-3-carboxamide

    13. Sr-141716

    14. Rml78en3xe

    15. Chembl111

    16. Rimonabant (sr141716)

    17. Chebi:34967

    18. Ncgc00164572-01

    19. Sr-14171

    20. [3h]sr141716a

    21. 158681-13-1 (hcl)

    22. [3h]rimonabant

    23. Dsstox_cid_26453

    24. Dsstox_rid_81627

    25. Dsstox_gsid_46453

    26. 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxylic Acid Piperidin-1-ylamide

    27. Acomplia (tn)

    28. Rimonabant [inn]

    29. Smr003500713

    30. Cas-168273-06-1

    31. Unii-rml78en3xe

    32. Rimonabant (jan/usan/inn)

    33. Rimonabant [usan:inn:jan]

    34. 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-1h-pyrazole-3-carboxamide

    35. Rimonabant- Bio-x

    36. 1h-pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-

    37. Sr141,716a

    38. Rimonabant [mi]

    39. Rimonabant [jan]

    40. 1h-pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-, Monohydrochloride

    41. Rimonabant - From Sample

    42. Rimonabant [usan]

    43. Rimonabant(sr141716)

    44. Rimonabant [mart.]

    45. 5-(p-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidinopyrazole-3-carboxamide

    46. Rimonabant [who-dd]

    47. Schembl38637

    48. Gtpl743

    49. Mls004774043

    50. Mls006011772

    51. Rimonabant [ema Epar]

    52. Dtxsid3046453

    53. Bdbm21278

    54. Ex-a688

    55. Hms3604m05

    56. Hms3657o15

    57. Bcp07803

    58. Zinc1540228

    59. Tox21_112200

    60. Ac-731

    61. Bbl030198

    62. Mfcd04034714

    63. Nsc791533

    64. S3021

    65. Stk642500

    66. Akos005266728

    67. Tox21_112200_1

    68. Am84578

    69. Ccg-269385

    70. Cs-0645

    71. Db06155

    72. Nsc-791533

    73. Sb19549

    74. 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(1-piperidyl)pyrazole-3-carboxamide

    75. 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidino-1h-pyrazole-3-carboxamide

    76. Ncgc00164572-02

    77. As-37280

    78. Br164345

    79. Hy-14136

    80. Ac-163720

    81. Db-011649

    82. B1429

    83. Ft-0631194

    84. R0205

    85. Sw220167-1

    86. 81r131

    87. D05731

    88. Ab01566860_01

    89. A810956

    90. L000572

    91. Q412529

    92. Sr-01000884001

    93. J-010440

    94. Sr-01000884001-1

    95. (n-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide

    96. 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(1-piperidinyl)-3-pyrazolecarboxamide

    97. 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidin-1-yl-pyrazole-3-carboxamide

    98. N-piperidino-5-(4-chlorophenyl)-1(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide

    99. N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide

    100. 1h-pyrazole-3-carboxamide,5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-

    101. 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1h-pyrazole-3-carboxylic Acid Piperidin-1-ylamide

    102. Ay6

    2.4 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 463.8 g/mol
    Molecular Formula C22H21Cl3N4O
    XLogP36.5
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count4
    Exact Mass462.078094 g/mol
    Monoisotopic Mass462.078094 g/mol
    Topological Polar Surface Area50.2 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity583
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia.

    As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5. 1).

    As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5. 1).

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    In the RIO-North America trial, 3040 patients were randomized to receive either placebo or one of two doses of rimonabant (5 mg or 20 mg per day). Patients taking 20 mg rimonabant had significant weigh loss, decrease in waist circumference, improved insulin sensitivity, and increases in HDL cholesterol, compared to patients on placebo.

    5.2 MeSH Pharmacological Classification

    Anti-Obesity Agents

    Agents that increase energy expenditure and weight loss by neural and metabolic regulation. (See all compounds classified as Anti-Obesity Agents.)

    Cannabinoid Receptor Antagonists

    Compounds that inhibit or block the activity of CANNABINOID RECEPTORS. (See all compounds classified as Cannabinoid Receptor Antagonists.)

    5.3 ATC Code

    A08AX01

    A08AX01

    A - Alimentary tract and metabolism

    A08 - Antiobesity preparations, excl. diet products

    A08A - Antiobesity preparations, excl. diet products

    A08AX - Other antiobesity drugs

    A08AX01 - Rimonabant

    5.4 Absorption, Distribution and Excretion

    Absorption

    Undetermined

    5.5 Metabolism/Metabolites

    Hepatic, CYP3A4 involved.

    5.6 Biological Half-Life

    6 to 9 days with normal BMI and 16 days if BMI is greater than 30

    5.7 Mechanism of Action

    Rimonabant is a specific CB1 cannabinoid receptor antagonist. There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders.